Join medical device and digital health entrepreneurs, CEOs of venture-backed companies, and business development executives from large Medtech and digital health companies, as well as angels, venture capitalists, and...more
5/8/2025
/ Acquisitions ,
Antitrust Violations ,
Artificial Intelligence ,
CEOs ,
Digital Health ,
Emerging Growth Companies ,
Equity Compensation ,
Events ,
Executive Compensation ,
Exit Strategies ,
Food and Drug Administration (FDA) ,
Innovation ,
Investors ,
Med Tech ,
Medical Devices ,
Mergers ,
Patents ,
Startups ,
Venture Capital
The United States Patent and Trademark Office (USPTO) announced the finalized patent fee increases which will be taking effect on January 19, 2025. These fee changes include an average increase of 7.5 percent in fee...more
In a precedential decision issued on August 13, 2024, the U.S. Court of Appeals for the Federal Circuit held that a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued,...more
On December 8, 2023, the National Institute of Standards and Technology (NIST) released the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (guidance) to the public for comment. The...more
On November 7, 2023, the Federal Trade Commission (FTC) sent notice letters1 to 10 brand drug manufacturers of drug-device combination products, including drugs delivered by asthma inhalers, epinephrine autoinjectors, and...more
Amgen Inc. et al. v. Sanofi et al., No. 22-157 (U.S. 2023) -
The U.S. Supreme Court, in a unanimous decision, has affirmed the Federal Circuit’s decision invalidating Amgen’s patent claims covering a genus of antibodies...more
Amgen Inc. v. Sanofi, No. 20-1074 (Fed. Cir. 2021)
The Federal Circuit recently issued a precedential decision on the validity of antibody epitope claims covering Amgen's Repatha® (evolocumab) product. The court found...more
The United States Patent and Trademark Office (USPTO) is implementing a COVID-19 Prioritized Examination Pilot Program for small and micro entities. The program is intended to help independent inventors and small businesses...more
The U.S. Patent and Trademark Office (USPTO) today released its latest iteration of guidance—referred to as the "Interim Eligibility Guidance"—to its examiners. This guidance is aimed at assessing whether an invention claimed...more